Compare BridgeBio Pharma Inc (BBIO) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Home Depot Inc — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.27B), while Home Depot Inc trades at $337.45 (market cap $336.14B). The key difference: Home Depot Inc is far larger — about 20.7× BridgeBio Pharma Inc's market cap, and Home Depot Inc pays a 2.76% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | HD | |
|---|---|---|
Market Cap | $16.27B | $336.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $423.42 |
52-Week Low | $44.81 | $297.51 |
Enterprise Value | $17.82B | $397.69B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Home Depot (HD) trades at $337.11, down 1.8% on the day, with a bearish technical signal and mixed earnings history. The stock shows strong profitability with a net margin of 8.41% and ROE of 128.38%, but faces margin compression and weak big-ticket demand. Recent news highlights institutional selling and concerns over rising mortgage rates impacting home improvement spending.
The outlook is cautious due to near-term headwinds, but analyst consensus remains bullish with a $370.59 price target. Risks include housing market sensitivity and competitive pressures, while opportunities lie in Pro segment growth and dividend stability. Long-term prospects depend on economic resilience and execution against margin challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
